Franklin Resources
NGM

Franklin Resources’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Franklin Resources’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,100
Closed -$15.1K – 2746
2023
Q3 		$15.1K Sell
14,100
-19,338
-58% -$40K ﹤0.01% 2609
2023
Q2 		$86.6K Buy
+33,438
New +$119K ﹤0.01% 2554
2023
Q1 		– Sell
-16,500
Closed -$82.8K – 2408
2022
Q4 		$82.8K Buy
+16,500
New +$103K ﹤0.01% 2154

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources's NGM Position: Q4 2023 in Review

Franklin Resources sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2023, closing a stake of 14,100 shares — an estimated $15.1K sold.

Franklin Resources first reported a position in NGM in Q4 2022 and held it in 3 quarters. The position peaked at $86.6K in Q2 2023. 83 funds tracked by Wall St. Rank hold NGM as of Q4 2023.

  • Franklin Resources reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Franklin Resources sold 14,100 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $15.1K.
  • Franklin Resources first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Franklin Resources's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $86.6K in Q2 2023.
  • 83 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Franklin Resources's 13F filing for Q4 2023, filed 9 Feb 2024.